risks, page-7

Good thread and not truer words spoken.

Nazzy, yes there are heaps of supposed sure things that have failed, maybe that's why this one is still quite low with regards to market cap. But on the fip side there are many times where the market has simply overlooked the potential or waited for a more convincing entry, heck if TIS start to break into the potential $4B spent on diabetic, venous and pressure ulcers there will be plenty of time to take a position. Myself I like to get in beforehand, after doing everything in my power to make sure the risk is as low as I can tolerate, then ride the upside all the way.

The market may also be hanging back due to the fact that TIS is about 18 months behind its trial schedule after the contamination of product and regulatory delays. All this seems to be behind them now and things are progressing really well. I also like the fact that they fall under the device classification, after these new trials it may not be long to market throughout Europe etc.

I like a little snippet that was in the June Bioshares report that read along the lines like this:

>>> It is unheard of that none of the patients don't get any worse, according to UK wound healing expert Prof Keith Harding, in a chronic skin ulcer trial such as the VitroGro trials, said Mercer. He said the product is becoming predictable and before the trials started he didn't believe the level of results so far could be achieved <<<

I also like the fact that Prof Michael Stacey from the Vascular Research Laboritory wanted to continue treating patients with VitroGro after the previous clinical studies. So I guess while nothing is certain in life we all have to make judgement calls along the way and to me I'm happy enough to make this one with my hard earned. As Writer (well looks who's here:) mentioned also once these guys negotiate a licensing deal/commercialisation partner in the wound healing segment, in which they are in multiple discussions, then we will see some fireworks I believe:)

SuperT, yes it's great to see Mel Bridges (ACL Chairman) here as a director.